The next role of Linda Yaccarino Post Leaving X as Director General will be another general role at Emed popular healthAI-eccracker building a ie curtionnic platform for patients using GLP-1s.
Yaccarino was a longtime advertisement -an executive at NBCUniversal, but let join X as CEO for two years, where she managed to have A positive impact In the troubled advertising model of the social network, despite her and Elon Musk’s shared approach to minimize content moderation.
Although Yaccarino has no experience in Health Tech, Emed said in a press release that they were looking for her because of her “undisputed ability to negotiate new partnerships”-it certainly also helps that her tenor at X made her known in the TE Worldnic world, attracting more eyes to the start.
Med Before Produced a technology platform that was designed to be used with domestic Covid-19 fast antigen trials, guiding users through the process to manage these tests correctly. Now, Emed is focused on GLP-1S, the drug class like Ozempic, usable for both weight management and type II diabetes treatment.
“To be a leader in today’s medical market, companies need to have a timid tenacity that allows them to not only grow, but also to be brave enough to advance and redefine an entire industry,” Yaccarino said in a press release. “We are very positioned to be that tenacious leader, striving for our ultimate goal of improving global health results through our innovative services and platforms.”
